Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic Therapy
Top Cited Papers
- 19 January 2010
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 55 (3), 213-220
- https://doi.org/10.1016/j.jacc.2009.03.095
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Beta-blockade intolerance in anthracyclin-induced cardiomyopathyInternational Journal of Cardiology, 2006
- Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart FailureThe Journal of Heart and Lung Transplantation, 2005
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast CancerThe New England Journal of Medicine, 2003
- Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapyJournal of the American College of Cardiology, 2000
- Underlying Causes and Long-Term Survival in Patients with Initially Unexplained CardiomyopathyThe New England Journal of Medicine, 2000
- Doxorubicin‐induced cardiomyopathy treated with carvedilolClinical Cardiology, 1998
- Relation Between Gender, Etiology and Survival in Patients With Symptomatic Heart FailureJournal of the American College of Cardiology, 1996
- Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathyThe Lancet, 1996
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976